Ann: MSB Highlights Key 2019 Priorities at U.S. Biotech Showcase, page-88

What’s going on with Mesoblast?
Alan KohlerNovember 27, 2018CEO Interviews

Extract

Alan Kohler

I wonder, Silviu, whether the message from this to you is that you have a serious credibility problem with the market. Because you’ve been plugging away at this for so long now, almost 15 years, do you feel like if they’re not going to believe you on this, they’re not actually giving you the benefit of the doubt on something like this, then maybe you’ve got a credibility problem?
Silviu Itescu

Obviously, as I said to you, credibility comes with results, so you have to put the runs on the board and then credibility comes with that. A partnership deal in the short term would obviously provide the kind of credibility that the market’s looking for. That’s probably more important than interpretation of clinical data.

..................

From the above, the way I interpret it SI is saying the next move is a deal in the short term to gain credibility...